Cutaneous Vasculopathy as an Adverse Effect of the Anti-Vascular Endothelial Growth Factor Agent Axitinib.
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Veronica J
VJ
Shi
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut2Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Anjela
A
Galan
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Ian D
ID
Odell
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Jennifer N
JN
Choi
D000077784:Axitinib; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007191:Indazoles / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D017445:Skin Diseases, Vascular / Q000139:chemically induced* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000077784:Axitinib